Cellular & Molecular Immunology, Published online: 22 April 2024; doi:10.1038/s41423-024-01156-8Inhibition of METTL3 in macrophages provides protection against intestinal inflammation
Background
Studies showed that vascular endothelial growth factor (VEGF) inhibitors could improve therapeutic efficacy of PD-1/PD-L1 antibodies by transforming the immunosuppressive tumor microenvironment (TME) into an immunoresponsive TME. Ivonescima…
Background
Colitis caused by checkpoint inhibitors (CPI) is frequent and is treated with empiric steroids, but CPI colitis mechanisms in steroid-experienced or refractory disease are unclear.
Methods
Using colon biopsies and blood from predominantly …
Science Immunology, Volume 9, Issue 94, April 2024.
Science Immunology, Volume 9, Issue 94, April 2024.
Science Immunology, Volume 9, Issue 94, April 2024.
Background
Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for predicting treatment o…
Background
Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite the…
Cellular & Molecular Immunology, Published online: 19 April 2024; doi:10.1038/s41423-024-01163-9Lkb1 orchestrates γδ T-cell metabolic and functional fitness to control IL-17-mediated autoimmune hepatitis
BackgroundThe currently available medications for treating membranous nephropathy (MN) still have unsatisfactory efficacy in inhibiting disease recurrence, slowing down its progression, and even halting the development of end-stage renal disease. There…
